Regeneron Pharmaceuticals Stock Forecast, Price & News

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Regeneron Pharmaceuticals?

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Regeneron Pharmaceuticals.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, November 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) issued its earnings results on Thursday, August, 5th. The biopharmaceutical company reported $25.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.81 by $16.99. The biopharmaceutical company had revenue of $5.14 billion for the quarter, compared to analyst estimates of $3.90 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 50.43% and a net margin of 50.11%.
View Regeneron Pharmaceuticals' earnings history.

How has Regeneron Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, REGN stock has increased by 23.2% and is now trading at $572.36.
View which stocks have been most impacted by COVID-19.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its Board of Directors has approved a stock buyback program on Tuesday, November 5th 2019, which allows the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy up to 2.9% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its stock is undervalued.

What price target have analysts set for REGN?

16 equities research analysts have issued 12 month target prices for Regeneron Pharmaceuticals' stock. Their forecasts range from $565.00 to $842.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $699.19 in the next year. This suggests a possible upside of 22.2% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

• Leonard S. Schleifer, Co-President, Chief Executive Officer & Director
• George Damis Yancopoulos, Co-President, Director & Chief Scientific Officer (LinkedIn Profile)
• Patrice Gilooly, Senior VP-Quality Assurance & Operations
• Robert E. Landry, Chief Financial Officer & Executive VP-Finance (LinkedIn Profile)
• Neil Stahl, Executive VP-Research & Development

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Who are some of Regeneron Pharmaceuticals' key competitors?

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Repligen (RGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of REGN's competitors.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Chevy Chase Trust Holdings Inc. (0.21%), Virginia Retirement Systems ET AL (0.11%), Pinnacle Associates Ltd. (0.09%), DekaBank Deutsche Girozentrale (0.09%), Robeco Institutional Asset Management B.V. (0.05%) and Strs Ohio (0.04%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends for Regeneron Pharmaceuticals.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, DNB Asset Management AS, Strs Ohio, Pinnacle Associates Ltd., Exchange Traded Concepts LLC, Unison Advisors LLC, Palouse Capital Management Inc., and Oregon Public Employees Retirement Fund. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Arthur F Ryan, Bonnie L Bassler, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, N Anthony Coles, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was acquired by a variety of institutional investors in the last quarter, including Chevy Chase Trust Holdings Inc., Assenagon Asset Management S.A., Robeco Institutional Asset Management B.V., DekaBank Deutsche Girozentrale, Anderson Hoagland & Co., Pensionfund Sabic, Fifth Third Bancorp, and Private Advisor Group LLC.
View insider buying and selling activity for Regeneron Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $572.36.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $61.22 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Where are Regeneron Pharmaceuticals' headquarters?

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at (914) 847-7000 or via email at [email protected].